Concomitant medications and outcomes of bispecific T-cell engager therapy: A propensity-matched study of tarlatamab in ES-SCLC

Study limitation reported by the research below: “Cohort sizes per matched arm are modest (112–229), limiting statistical power for subgroup analyses and secondary endpoints like ICANS.”